A 66-year-old man with sexual dysfunction

JAMA

Volumn 291, Issue 24, 2004, Pages 2994-3003

  Morgentaler, Abraham ^a  

^a Men's Health Boston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL; YOHIMBINE; PIPERAZINE DERIVATIVE;

AGED; CARDIOVASCULAR EFFECT; CASE REPORT; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HIGH RISK PATIENT; HUMAN; MALE; NOSE CONGESTION; PENIS PROSTHESIS; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SIDE EFFECT; VACUUM; ARTICLE; BIOPSY; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; HORMONE SUBSTITUTION; HYPOGONADISM; IMPOTENCE; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE; PROSTATE TUMOR; RISK;

AGED; BIOPSY; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSTATE; PROSTATIC NEOPLASMS; RISK; TESTOSTERONE;

EID: 2942737042     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.24.2994     Document Type: Conference Paper

References (83)

1. Morgentaler A. Male impotence. Lancet. 1999;354:1713-1718.
2. Morgentaler A. The Viagra Myth: The Surprising Impact on Love and Relationships. San Francisco, Calif: Jossey Bass/Wiley; 2003.
3. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397-1414.
4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
5. Koskimaki J, Hakama M, Huhtala H, Tammela TL. Effect of erectile dysfunction on frequency of intercourse: a population based prevalence study in Finland. J Urol. 2000;164:367-370.
6. Parazzini F, Menchini Fabris F, Bortolotti A, et al. Frequency and determinants of erectile dysfunction in Italy. Eur Urol. 2000;37:43-49.
7. Marumo K, Nakashima J, Murai M. Age-related prevalence of erectile dysfunction in Japan: assessment by the International Index of Erectile Function. Int J Urol. 2001;8:53-59.
8. Dunn KM, Croft PR, Hackett GI. Sexual problems: a study of the prevalence and need for health care in the general population. Fam Pract. 1998;15:519-524.
9. Chew KK, Earle CM, Stuckey BGA, Jamrozik K, Keogh EJ. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res. 2000;12:41-45.
10. Safarinejad MR. Prevalence and risk factors for erectile dysfunction in a population-based study in Iran. Int J Impot Res. 2003;15:246-252.
11. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the Health Professionals Follow-up Study. Ann Intern Med. 2003;139:161-168.
12. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-1813.
13. Silvestri A, Galleta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24:1928-1932.
14. Solomon H, Man J, Wierzbicki AS, O'Brien T, Jackson G. Erectile dysfunction: cardiovascular risk and the role of the cardiologist. Int J Clin Pract 2003;57:96-99.
15. Kawanishi Y, Lee KS, Kimura K, et al. Screening of ischemic heart disease with cavernous artery blood flow in erectile dysfunctional patients. Int J Impot Res. 2001;13:100-103.
16. Morgantaler A, Crews D. Role of the anterior hypothalamus-preoptic area in the regulation of reproductive behavior in the lizard, Anolis carolinensis: implantation studies. Horm Behav. 1978;11:61-73.
17. Saenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res. 2002;14(suppl 1):S6-S10.
18. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LI. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, non-cholinergic neurotransmission. N Engl J Med. 1992;326:90-94.
19. Corbin JD, Francis SH, Webb DJ. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 2002;60(2 suppl 2):4-11.
20. Tiefer L, Schuetz-Mueller D. Psychological issues in diagnosis and treatment of erectile disorders. Urol Clin North Am. 1995;22:767-773.
21. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-492.
22. Morgentaler A, Rhoden EL. Risks of testosterone replacement. N Engl J Med. 2004;350:2004-2006.
23. Morley JE, Patrick P, Perry HM 3rd. Evaluation of assays available to measure free testosterone. Metabolism. 2002;51:554-559.
24. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of one year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170:2348-2351.
25. Hatzichristou DG, Hatzimouratidis K, Ioannides E, Yannakoyorgos K, Dimitdadis G, Kalinderis A. Nocturnal penile tumescence and rigidity monitoring in young potent volunteers: reproducibility, evaluation criteria and the effect of sexual intercourse. J Urol. 1998;159:1921-1926.
26. Karacan I, Salis PJ, Ware JC, et al. Nocturnal penile tumescence and diagnosis in diabetic impotence. Am J Psychiatry. 1978;135:191-197.
27. Lue TF, Hricak H, Marich KW, Tanagho EA. Vasculogenic impotence evaluated by high-resolution ultrasonography and pulsed Doppler spectrum analysis. Radiology. 1985;155:777-781.
28. Hellstrom WJG, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002;23:763-771.
29. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003;62:121-125.
30. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168(4 pt 1):1332-1336.
31. Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res. 2002;14:466-471.
32. Rendell MS, Rajfer J, Wickers PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA. 1999;281:421-426.
33. Blander DS, Sanchez-Ortiz RF, Wein AJ, Broderick GA. Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int J Impot Res. 2000;12:165-168.
34. Viagra [package insert information]. In: Physicians'Desk Reference. 58th ed. Montvale, NJ: Thompson PDR; 2004:2664.
35. Levitra prescribing information. Available at: http://www.univgraph.com/ bayer/inserts/levitra.pdf. Accessibility verified May 27, 2004.
36. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens. 2001;14:70-73.
37. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol. 2003;92(9A):37M-46M.
38. Gillies HC, Roblin D, Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol. 2002;86:131-141.
39. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellika PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA. 2002;287:719-725.
40. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002;40:2006-2012.
41. Hermann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med. 2000;342:1622-1626.
42. Wysowski DK, Frinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol. 2002;89:1331-1334.
43. Shakir SAW, Wilton LV, Boshier A, Layton D, Heeley E. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ. 2001;322:651-652.
44. Muller JE, Mittleman MA, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. JAMA. 1996;275:1405-1409.
45. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol. 2000;86:62F-68F.
46. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938.
47. Virag R, Shoukry K, Floresco J, Nollet F, Greco E. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol. 1991;145:287-292.
48. von Heyden B, Donatucci CF, Marshall GA, et al. A prostaglandin E1 doseresponse study in man. J Urol. 1993;150:1825-1828.
49. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med. 1996;334:873-877.
50. Bennet AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol. 1991;146:1564-1565.
51. Sexton WJ, benedict JF, Jarow JP. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urol. 1998;159:811-815.
52. Rajpurkar A, Dhabuwala CB. Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice. J Urol. 2003;170:159-163.
53. Porst H. Transurethral alprostadil with MUSE (Medicated Urethral System for Erection) vs intracavernous alprostadil-a comparative study in 103 patients with erectile dysfunction. Int J Impot Res. 1997;9:187-192.
54. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol. 1997;15:78-82.
55. Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol. 2001;166:932-937.
56. Carson CC, Mulcahy JJ, Govier FE, and the AMS 700CX Study Group. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. J Urol. 2000;164:376-380.
57. Goldstein I, Newman L, Baum N et al. Safety and efficacy outcome of Mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol. 1997;157:833-839.
58. Khoudary K, Morgentaler A. Design considerations in penile prostheses: the American Medical Systems product line. J Long Term Eff Med Implants. 1997;7:55-64.
59. Dula E, Bukofzer S, Perdok R, George M, for the Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol. 2001;39:558-563.
60. Guay AT, Spark RF, Jacobson J, Murray FT, Geisser ME. Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial. Int J Impot Res. 2002;14:25-31.
61. Morley JE, Kaiser FE, Perry HM, et al. Longitudinal changes in testosterone, LH and FSH in healthy older men. Metabolism. 1997;46:410-413.
62. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731.
63. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2839-2855.
64. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R, for the North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88:2673-2681.
65. McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91:69-74.
66. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84:3469-3478.
67. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet. 1977;2:262-263.
68. Bagatell CJ, Bremner WJ. Drug therapy: androgens in men-uses and abuses. N Engl J Med. 1996;334:707-714.
69. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. Circulation. 2000;102:1906-1911.
70. Webb CM, McNeill JG, Hayward CS, Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100:1690-1696.
71. Gyllenborg J, Rasmuassen SL, Borch-Johnsen K, Heitmann BL, Skakkebaek NE, Juul A, Cardiovascular risk factors in men: the role of gonadal steroids and sex hormone-binding globulin. Metabolism. 2001;50:882-888.
72. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001;111:261-268.
73. Huggins CB, Stevens RB, Hodges CV. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209.
74. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003;24:299-311.
75. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate. 1995;27:25-31.
76. Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer. 1999;86:312-315.
77. Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev. 2001;23:42-58.
78. Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118-1126.
79. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003;349:335-342.
80. Schroder FH, Kranse R. Verification bias and the prostate-specific antigen test-is there a case for a lower threshold for biopsy? N Engl J Med. 2003;349:393-395.
81. Morgentaler A, Bruning CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996;276:1904-1906.
82. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000;163:824-827.
83. Chamness SL, Ricker DD, Crone JK, et al. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril. 1995;63:1101-1107.